Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
This study has been completed.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00316732
First received: April 20, 2006
Last updated: October 18, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.
| Condition | Intervention | Phase |
|---|---|---|
|
Benign Prostatic Hyperplasia Prostatic Hyperplasia |
Procedure: IPSS Questionnaire Procedure: EQ-5D Questionnaire |
Phase 4 |
| Study Type: | Interventional |
| Official Title: | An Observational Study to Assess the Effectiveness of Avodart™(Dutasteride)in Subjects With Benign Prostatic Hyperplasia in Day to Day Clinical Practice |
Resource links provided by NLM:
Further study details as provided by GlaxoSmithKline:
Eligibility| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia).
- Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH.
- Patients must only enter the study after the decision to prescribe dutasteride has been undertaken.
Exclusion criteria: None specified
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00316732
Locations
| United Kingdom | |
| GSK Investigational Site | |
| Exeter, Devon, United Kingdom, EX2 5DW | |
| GSK Investigational Site | |
| Plymouth, Devon, United Kingdom, PL6 8DH | |
| GSK Investigational Site | |
| Colchester, Essex, United Kingdom, CO4 5JL | |
| GSK Investigational Site | |
| Stevenage, Hertfordshire, United Kingdom, SG2 4AB | |
| GSK Investigational Site | |
| Manchester, Lancashire, United Kingdom, M8 5RB | |
| GSK Investigational Site | |
| Manchester, Lancashire, United Kingdom, M13 9WL | |
| GSK Investigational Site | |
| Leicester, Leicestershire, United Kingdom, LE5 4PW | |
| GSK Investigational Site | |
| Leytonstone, London, United Kingdom, E11 1NR | |
| GSK Investigational Site | |
| Enfield, Middlesex, United Kingdom, EN2 8JL | |
| GSK Investigational Site | |
| Nottingham, Nottinghamshire, United Kingdom, NG5 1PB | |
| GSK Investigational Site | |
| Tauton, Somerset, United Kingdom, TA1 5DA | |
| GSK Investigational Site | |
| Sunderland, Tyne & Wear, United Kingdom, SR4 7TP | |
| GSK Investigational Site | |
| Sutton Coldfield, West Midlands, United Kingdom, B75 7RR | |
| GSK Investigational Site | |
| Birmingham, United Kingdom, B15 2TH | |
| GSK Investigational Site | |
| Bradford, United Kingdom, BD5 0NA | |
| GSK Investigational Site | |
| Bristol, United Kingdom, BS2 8HW | |
| GSK Investigational Site | |
| Hull, United Kingdom, HU16 5JD | |
| GSK Investigational Site | |
| Ilkeston, Derbyshire, United Kingdom, DE7 8LN | |
| GSK Investigational Site | |
| Leeds, United Kingdom, LS1 3EX | |
| GSK Investigational Site | |
| London, United Kingdom, EC1 7BE | |
| GSK Investigational Site | |
| London, United Kingdom, W18 6BJ | |
| GSK Investigational Site | |
| London, United Kingdom, NW3 2QG | |
| GSK Investigational Site | |
| Torquay, United Kingdom, TQ2 7AA | |
| GSK Investigational Site | |
| Wakefield, United Kingdom, WF1 4DG | |
Sponsors and Collaborators
GlaxoSmithKline
Investigators
| Study Director: | GSK Clinical Trials | GlaxoSmithKline |
More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00316732 History of Changes |
| Other Study ID Numbers: | 103500 |
| Study First Received: | April 20, 2006 |
| Last Updated: | October 18, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Keywords provided by GlaxoSmithKline:
|
Avodart IPSS BPH |
dutasteride EQ-5D Observational |
Additional relevant MeSH terms:
|
Prostatic Hyperplasia Hyperplasia Prostatic Diseases Genital Diseases, Male Pathologic Processes |
Dutasteride 5-alpha Reductase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013